Past champ *Genprex, Inc. (GNPX)* could be on the verge of breaking out again. Here is what you need to know... Genprex, Inc is a

StockWireNews

Breaking News: Genprex, Inc. (GNPX) Signs Exclusive License Agreement, Could Be Major Breakout Candidate

This Low Float Stock Has A $5.00 Analyst Price Target And Major Upside Potential

February 11th

Good Morning,

Past champ *Genprex, Inc. (GNPX)* could be on the verge of breaking out again. Here is what you need to know: breaking news this AM regarding the signing of an exclusive license agreement.

Genprex, Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy.

And, on January 21st of 2020, I brought this stock to your attention early that morning only to watch it make a 2 day run from an open of $1.20 to a high of $2.00 for a surge of 66.67%.

Now, fast-forward to today. I think there is potential that this stock could run again due to 4 major catalysts. Here they are:

#1 GNPX Catalyst - Recent FDA Fast Track News

Last month Genprex dropped a bombshell news release. Check it out:

Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

Lung cancer is the world’s leading cause of cancer deaths

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso®, which had worldwide sales in 2018 of $1.86Bn, $2.31Bn in the first 9 months of 2019 and is currently AstraZeneca’s highest grossing product) for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone. Oncoprex is comprised of the TUSC2 (Tumor Suppressor Candidate 2) gene complexed with a lipid nanoparticle. TUSC2 is the active agent in Oncoprex.

Read the full article here.

-----

#2 GNPX Catalyst - Analyst $5.00 Price Target

Cosme Ordonez, an analyst with Noble Capital Markets, is bullish on Genprex and has provided an Outperform rating on the Austin, Texas company as well as a $5 price target on the view that further trials with humans for its lead drug Oncoprex in combination with Erlotinib (Tarceva) in 2020 will advance its prospects for commercialization.

On top of this, the Noble team are hopeful about the start of human clinical trials this year that will assess the ability of Oncoprex, working together with Merck’s blockbuster cancer drug Keytruda, to curb the corrosive spread of lung cancer.

-----

#3 GNPX Catalyst - Low Float Share Structure

According to Yahoo Finance, GNPX currently has an approximate 6.41Mn shares in its float.

As we've seen in previous stock profiles, a low float can lead to explosive price spiking in the short-term from volatility.

Biotech stocks are very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.

Could the next big news coming from the GNPX camp be the spark to send share prices flying???

-----

#4 GNPX Catalyst - A Potential Channel Forming?

Since GNPX's initial eruption back in January, it has not dropped below $1.00 again.

That means that since the 21st, GNPX has been in a potential channel between $1.04-$2.00.

Check it out:

image

Currently trading towards the bottom portion of the channel, GNPX could be primed for its next move towards the top ($2.00).

More reasons it could make its next move back up the charts is because the stock is displaying multiple bullish short-term technical indicators:

  • 20-Day Simple Moving Average
  • 20 to 50-Day MACD Oscillator
  • 20 to 100-Day MACD Oscillator
  • 20 to 200-Day MACD Oscillator

Additionally, on top of Barchart reporting GNPX as a "100% BUY%" in the short-term, its own "TrendSpotter" composite indicators has been triggered as a "BUY."

-----

More About The Company: Genprex, Inc.

From the company website:

Genprex is a clinical stage gene therapy company committed to pioneering a new approach to treating cancer. We are developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The nanovesicles are then administered intravenously and are taken up by tumor cells where they express proteins that are missing or found in low quantities.

Our lead product candidate, Oncoprex™, targets non-small cell lung cancer. This initial cancer target represents about 85 percent of all lung cancers and causes more deaths each year than any other type of cancer. Lung cancer is the second most common form of cancer, and the five-year survival rate for late stage lung cancer has not improved substantially in a quarter century. Research indicates that our platform technologies may deliver a number of other cancer fighting genes, alone or in combination with other cancer therapies, to combat additional types of cancer.

Clinical Trials: R&D Pipeline

We are developing Oncoprex, our lead product candidate, to be administered with erlotinib for NSCLC. We are also conducting preclinical research with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, we have conducted and plan to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of our immunogene therapy platform. Our current research and development pipeline is shown below.

image

https://www.genprex.com/

-----

Additional GNPX Info

Blockbuster Potential

Even though gene therapy is closing in on cancer, it remains as yet an unpredictable industry. However, biotech companies are in a feverish hunt for breakthroughs, and gene therapy could hold the keys. Tremendous advances have been made in gene-based therapeutics, and companies, such as Genprex Inc. (NASDAQ: GNPX), with the potential to make breakthroughs could deliver blockbuster returns.

Cutting-Edge Platform

Most currently approved cancer regimens target only single molecules, or a single specific genetic abnormality. Oncoprex’s multimodal mechanism of action interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes the pathways for cell death in cancer cells and modulates the immune response against cancer cells. Genprex clinical data indicate that Oncoprex, in combination with targeted therapies and immunotherapies, is significantly more effective than single drugs alone. Oncoprex has also demonstrated fewer side effects and less toxicity than many other lung cancer drugs.

Currently approved targeted therapies for advanced non-small cell lung cancer are only effective in a minority of patients, and eventually most patients become resistant to the treatments. Roughly 80% of lung cancers are non-small cell lung cancer, and the dismal 1% five-year survival rates haven’t improved in over a quarter century.

Genprex is well into Phase II clinical trials with Oncoprex for the treatment of the deadliest type of tumor, non-small cell lung cancer (NSCLC). Preliminary results from the ongoing trial to date are encouraging. Using Oncoprex in combination with Roche’s erlotinib showed disease control rates of 78%, which substantially exceed the 58% disease control rates demonstrated in other drug combination trials.

In addition, more than 40% of patients had tumor regression, and one patient — out of nine evaluated to date in Genprex’s Phase II drug combination trial — experienced what’s called a complete response. The patient, suffering with metastatic NSCLC, had complete disappearance of both the lung primary tumor as well as the metastasized cancer in the lung, liver and lymph nodes.

Genprex’s cutting-edge platform for the targeted delivery of gene therapeutics also has wide-ranging potential applications for the treatment of various other types of cancer, such as head and neck, renal cell (kidney), glioblastoma and soft-tissue cancer, among others.

Genprex holds more than 30 patents and 2 patents pending for its platform technologies and targeted molecular therapies. The company’s promising pipeline includes Oncoprex in combination with another cancer drug, Tarceva, in a Phase II clinical trial; and Oncoprex Immunogene therapy in preclinical development.

The company is conducting ongoing research to find biomarkers to identify patients most likely to benefit from Genprex treatments, as well as other drugs that will be synergistic with Genprex gene therapies. Given the enormous potential and vast unmet medical need, Genprex plans to apply for Fast Track, Breakthrough or RMAT designation from the FDA.

What’s Next?

Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials.

If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.

Should such a strategic partnership to commercialize Genprex’s technology transpire, it could potentially generate enormous value for the company’s shareholders.

-----

image

GNPX displays potential to be today's big time breakout star. Get it on your radar now before it's too late.

Sincerely,

Kai Parker

StockWireNews


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at www.stockwirenews.net/disclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com ("SCF") and an interest in the limited liability company that owns and operates fierce analyst . com ("FI"). From time to time, non-affiliated third parties hire Stock Wire News, SCF and/or FI jointly to publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC (a non affiliated 3rd party), StockWireNews has been hired for a one day period on 1/21/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockWireNews LLC and Venado Media, LLC (a non affiliated 3rd party), StockWireNews has been hired for a one day period on 2/11/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid forty-six thousand USD via bank wire transfer. We own zero shares of (GNPX). To date, we have now been compensated a total of sixty-eight thousand five hundred USD to disseminate information about (GNPX).